It’s time for reality to catch up to the promise of machine learning in medicine. This means fully integrating molecular and clinical data for improved patient outcomes - in clinical trials and at the bedside. We are building the engineering layer to enact algorithms into clinical practice.
Get the right intervention, to the right patient, at the right time.
Ritankar is the founder and CEO of Dascena. While a PhD student at the University of Cambridge, Ritankar saw that very few AI algorithms developed in the lab reached the bedside. He believed with more practically designed algorithms and adequate implementation infrastructure; the promise of machine learning could finally reach patients. With that vision, he founded Dascena at the age of 19. Dascena’s algorithms today are used by leading healthcare providers, pharmaceutical companies and diagnostic manufacturers. As a scientist, Ritankar has authored over 25 peer-reviewed publications, and was the youngest principal investigator funded by the NIH. He holds an MSc in biomedical engineering from Oxford University as well as degrees in bioengineering and chemical biology from the University of California, Berkeley, where he received the University Medal.
Qingqing leads the development of Dascena’s compliant and scalable clinical data pipelines and research efforts in applying machine learning techniques to healthcare and medicine. He also oversees Dascena’s IT security and compliance practices. He previously worked as a senior staff data scientist at Primer AI, where he focused on building complex and high-performance analytical pipelines that bring state-of-the-art natural language processing models into production for Fortune 500 organizations and federal intelligence agencies. He has a Ph.D. in Astrophysics from Vanderbilt University, where he researched large-scale galaxy distribution using computer simulations and datasets of millions of galaxies.
Jana oversees scientific communications and KOL relationships at Dascena. Her responsibilities include preparation of scientific manuscripts and posters, FDA submissions, and reports to federal agencies such as NIH and BARDA. Jana joined Dascena from Catalyst Biosciences, where she held roles of increasing responsibility on the scientific team. Prior to Catalyst Biosciences, she was a postdoc in the Kuo lab at Stanford, where she discovered a previously unknown function of the vascular endothelial growth factor (VEGF) as a repressor of hepatic erythropoietin expression. Jana holds a PhD in biophysical chemistry from the University of California, Berkeley and a BA in chemistry from Princeton University.
Steve has over 30 years of experience in the biotech, pharma, and technology industries and was most recently a co-founder and the CEO of Kota Biotherapeutics, a startup incubated at Intellectual Ventures in Bellevue, WA. Prior to Kota, Steve was Vice President, Patent Counsel of the Biomedical Group at Intellectual Ventures. Previously, he was VP, General Counsel and Head of Business Development at Ceptyr, Inc. a biotechnology company. Steve also served as the Managing Counsel for IP and Licensing at Immunex Corp, which was acquired by Amgen. Prior to Immunex, he served as a patent attorney for the multinational pharmaceutical company, Hoffman La-Roche. Earlier in his career, Steve was an attorney in private practice and a process engineer at Raychem Corp. Steve holds a JD from Santa Clara University Law School and a BS in chemical engineering from the University of Michigan.
Jonathan oversees outreach to health systems for Dascena’s InSight sepsis algorithm and identification of new opportunities to monetize Dascena’s clinical database. In addition, Jonathan has also led business development efforts and negotiations for a strategic partnership with Danaher Corporation for a second generation sepsis algorithm. Jonathan dropped out of Calvin College where he was pursuing a degree in mechanical engineering to join Dascena, and previously started a social entrepreneurship business in college.
Carol is responsible for day-to-day company operations including HR, finance, and legal and compliance. She also oversees alliance management, health system integrations, and regulatory affairs and quality assurance activity. She helped develop Dascena’s rapid, low IT burden, direct-to-EHR integration process. Carol holds a BA in chemistry from Princeton University. Before Dascena, Carol worked alongside healthcare professionals at clinics, and she also spent time at the bench as an organic chemist specializing in medicinal chemistry and photocatalysis.
Cindy brings a diverse array of drug development and corporate strategy experience to Dascena as she works towards leveraging Dascena’s algorithms for biopharma and diagnostic applications. Before Dascena, Cindy was an Engagement Manager at L.E.K. Consulting, where she was a core member of the Life Sciences practice and advised both large and small biopharma companies on M&A strategy, asset diligence, portfolio optimization, and change management. Cindy holds a Ph.D. in Chemical Biology from UC Berkeley, and an A.B. from Harvard College.
Priya leads efforts to grow Dascena’s portfolio of business with health systems, diagnostics, and biopharma partners. This includes seeking and managing partnerships and other business opportunities in Diagnostics and BioPharma; establishing and communicating company strategy based on business and commercial analytics; as well as liaising with external parties including the FDA and other non-profits. Priya comes to Dascena with experience across the BioPharma value chain. In 19 years working at Roche/Genentech, Priya has deep operational experience across late stage drug development and commercialization. More recently she led the efforts to architect Roche Pharma’s Personalized Healthcare strategy and execution.